Authors: Dodd, PM McCaffrey, JA Mazumdar, M Scher, H Higgins, G Boyle, MG Herr, H Bajorin, DF

Citation: Pm. Dodd et al., Evaluation of drug delivery and survival impact of dose-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancer, CANCER INV, 18(7), 2000, pp. 626-634

Authors: Dodd, PM McCaffrey, JA Hilton, S Mazumdar, M Herr, H Kelly, WK Icasiano, E Boyle, MG Bajorin, DF

Citation: Pm. Dodd et al., Phase I evaluation of sequential doxorubicin plus gemcitabine then ifosfamide plus paclitaxel plus cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract, J CL ONCOL, 18(4), 2000, pp. 840-846

Authors: Dodd, PM McCaffrey, JA Herr, H Mazumdar, M Bacik, J Higgins, G Boyle, MG Scher, HI Bajorin, DF

Citation: Pm. Dodd et al., Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma, J CL ONCOL, 17(8), 1999, pp. 2546-2552

Authors: Bajorin, DF Dodd, PM Mazumdar, M Fazzari, M McCaffrey, JA Scher, HI Herr, H Higgins, G Boyle, MG

Citation: Df. Bajorin et al., Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy, J CL ONCOL, 17(10), 1999, pp. 3173-3181